MDMelissa A. Daubert

Melissa A. Daubert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Melissa A. Daubert has a total of 309 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association Between Predicting Risk of Cardiovascular Disease Events (PREVENT) Risk Scores and Subclinical Cardiovascular Disease: Insights From the Project Baseline Health Study

    by Gracia Fahed, Diona Gjermeni, Nicholas Cauwenberghs, Everton J. Santana, Bettia E. Celestin, Shadi P. Bagherzadeh, Kevin M. Alexander, Michael Salerno, Tatiana Kusnetsova, Svati H. Shah, et al.

    Background: The American Heart Association Predicting Risk of Cardiovascular Disease Events risk scores estimate cardiovascular disease (CVD) risk, including heart failure (HF) and atherosclerotic CVD (ASCVD) events. Whether they associate with subclinical CVD in an asymptomatic community population is unknown. Methods: We analyzed 1138 participants from the multicenter PBHS (Project Baseline Health Study) cohort, who underwent echocardiography and coronary artery calcium scoring and were free of known CVD. Subclinical CVD was defined as the presence of subclinical HF or subclinical coronary artery disease. Subclinical HF included left ventricular diastolic dysfunction, left ventricular hypertrophy, or low ejection fraction (0. Predicting Risk of CVD Events 10‐year risk score associations with subclinical CVD were assessed using logistic regression and area under the receiver operating characteristic curve analysis. Results: Median age was 52 (41–64) years; 64% were White; and 57% were women. Subclinical HF was found in 182 (16%) participants, predominantly with left ventricular diastolic dysfunction (14%). Diastolic dysfunction prevalence increased from 5.8% in low‐risk HF groups to 44.1% in intermediate‐/high‐risk HF groups. Each unit increase in 10‐year HF risk corresponded to 2.67‐fold higher odds of diastolic dysfunction (95% CI, 2.25–3.18; area under the curve, 0.81). Subclinical coronary artery disease was present in 466 (41%) participants, with prevalence increasing from 28.5% in low‐risk ASCVD groups to 79.3% in intermediate‐/high‐risk ASCVD groups. Each unit increase in 10‐year ASCVD risk was associated with 2.91‐fold higher odds of any coronary calcification (95% CI, 2.54–3.35; area under the curve, 0.80), increasing to 4.76‐fold for coronary artery calcium >100 (95% CI, 3.70–6.12; area under the curve, 0.86) and 5.60‐fold for coronary artery calcium >300 (95% CI, 3.89–8.05; area under the curve, 0.87). Conclusions: In an asymptomatic CVD‐free community sample, subclinical CVD was increasingly associated with higher 10‐year HF and ASCVD risks calculated by the Predicting Risk of CVD Events equations.


  • Impact of the 2025 ASE Guidelines on the Classification of LV Diastolic Dysfunction in the Community: A Project Baseline Health Study

    by Nancy Herrera-Leaño, Bettia Celestin, Everton J. Santana, Ryan Sandoval, Gracia Fahed, Patrick Khoury, Jack W. O’SUllivan, Tatiana Kuznetsova, Nicholas Cauwenberghs, Kenneth W. Mahaffey, et al.

    BACKGROUND: The 2016 American Society of Echocardiography (ASE) guidelines for left ventricular diastolic dysfunction (LVDD) classification resulted in a significant proportion of indeterminate classifications and grades. To address these limitations and incorporate new evidence, the ASE updated its recommendations in 2025. The impact of these revisions in community cohorts remains unclear. METHODS: We studied 1953 Project Baseline Health Study participants who underwent comprehensive transthoracic echocardiography. LVDD was classified using the 2016 and 2025 ASE recommendations. For the 2025 recommendations, fixed and age-specific thresholds were evaluated separately. We compared LVDD prevalence, reclassification patterns, associations with cardiovascular risk factors, and prognostic value for major adverse cardiovascular events over a median follow-up of 4.3 years. RESULTS: Median patient age was 50.6 years (Q1–Q3: 36.3–64.2); 56.3% of patients were female, 35.3% had hypertension, and 14.2% had diabetes. The prevalence of LVDD was higher with the 2025 recommendations than with the 2016 algorithm: fixed criteria 308 (15.8%), age-specific criteria 220 (11.3%) versus ASE 2016 154 (8.0%). Among 119 (6.1%) participants classified as indeterminate by the 2016 algorithm, the 2025 recommendations reclassified 51.2% as no LVDD and 31.8% as Grade 2 LVDD. Participants reclassified as no LVDD had event-free survival that was not statistically different from those without LVDD ( P =0.26), whereas those reclassified as Grade 2 had higher event rates (12.5% versus 3.8%; P =0.02). Major adverse cardiovascular events occurred in 98 (5.0%) participants over the follow-up period. LVDD by all classification approaches was independently associated with major adverse cardiovascular events after adjustment for baseline risk factors. CONCLUSIONS: The 2025 ASE recommendations identified more participants with LVDD than the 2016 algorithm without indeterminate classification or grading. LVDD by the 2025 classification was significantly associated with major adverse cardiovascular events, supporting the clinical relevance of the revised framework.


  • Stroke Risk After Bioprosthetic Aortic Valve Replacement in Aortic Stenosis: Systematic Review and Meta-Analysis

    by Tarek Bou Dargham, Sara Hassani, Brian Mac Grory, Melissa A. Daubert, Dylan Ryan, Tracy Truong, Mohamad B. Moumneh, Samantha J. Kaplan, Wuwei Feng, Nada El Husseini

    BACKGROUND: Stroke is a possible complication after bioprosthetic aortic valve replacement (AVR) for severe aortic stenosis (AS), impacting morbidity and mortality. Accurate estimates of the proportion of individuals who experience stroke within and beyond the periprocedural period after transcatheter AVR (TAVR), surgical AVR, and valve-in-valve (ViV) replacement are essential for management and prognostication. The objective was to determine the proportion of adults aged >18 who experienced an ischemic stroke after bioprosthetic AVR for AS. METHODS: A systematic search of MEDLINE, Embase, and Web of Science was conducted from database inception through March 2024. Studies reporting on stroke rates at least 90 days after bioprosthetic AVR for severe AS, including ViV procedures, and meeting predefined eligibility criteria were included. The pooled proportion of individuals experiencing a stroke was estimated for TAVR and ViV procedures, whereas comparative analyses between TAVR and surgical AVR were performed using mixed-effects models in studies directly comparing both procedures. RESULTS: Twenty-seven studies were included in the native AS treatment cohort, and 5 in the ViV subanalysis. In native AS, the pooled 30-day proportion of individuals who had a stroke after TAVR was 3.0% (95% CI, 2.5–3.9), with different studies reporting major and minor stroke proportions of 1.7% each. At 1 year, all stroke proportion was 5.0% (95% CI, 4.0–6.0), major stroke was 3.0%, and minor stroke was 2.0%. Comparative analysis demonstrated that TAVR was associated with significantly lower odds of all stroke at 30 days compared with surgical AVR (odds ratio, 0.73 [95% CI, 0.57–0.93]). No significant difference in the proportions of individuals who had a stroke was observed in TAVR versus surgical AVR at 1, 2, or 5 years. In the ViV cohort, the pooled 30-day and 1-year all stroke proportion after ViV was 2.0% (95% CI, 1.0–3.0) and 3.0% (95% CI, 2.0–6.0), respectively. CONCLUSIONS: This meta-analysis provides updated estimates of stroke after bioprosthetic AVR for AS, capturing risk beyond the early periprocedural period. Future studies should investigate the causes of long-term stroke post-AVR, the effects of different antithrombotic therapies on the risk of stroke, as well as the potential impact of these procedures on short and long-term cognitive function.


  • Open Access

    Bridging the Gap Between Genetic Cardiomyopathies and Pregnancy

    by Karen Flores Rosario, Merna Hussien, Phoenix Grover, Courtlyn Witte, Richa Agarwal, Jenna Skowronski, Johanna Quist-Nelson, Michelle M. Kittleson, Rachel Peragallo Urrutia, Melinda B. Davis, et al.


  • Open Access

    Diastolic Age: A Cardiac Biological Clock Derived from Echocardiography and the PREVENT Heart Failure Risk Score

    by Gracia Fahed, Nicholas Cauwenberghs, Everton Jose Santana, Rongrong Chen, Bettia Edith Celestin, Bruna Gomes, Sarah A. Short, Megan K. Carroll, Tatsuya Miyoshi, Kevin Michael Alexander, et al.

    Background: Among cardiac measures, diastolic parameters demonstrate the earliest and most consistent age-related changes. This can be leveraged to develop a continuous left ventricular (LV) Diastolic Age from routine echocardiographic parameters. Analogous to how epigenetic clocks weight molecular markers against mortality risk, we calibrated Diastolic Age by weighting echocardiographic features against the validated PREVENT–Heart Failure (HF) risk score. Methods: We analyzed 1,952 participants from the Project Baseline Health Study (median age 50 [36–64] years, 54% female). The measure was derived using partial least-squares regression anchored on PREVENT-HF and calibrated within a healthy reference subgroup. External validation was performed in the WASE (n=1,708) and Stanford Cardiovascular Aging (n=313) cohorts. Associations with ASE-defined LV diastolic dysfunction (LVDD), epigenetic clocks, and major adverse cardiovascular events (MACE) were examined. Results: Diastolic Age correlated strongly with chronological age (r=0.78) with robust external validation (WASE r=0.76; Stanford r=0.82; calibration slopes ≈1.0). It increased progressively across grades of diastolic dysfunction and discriminated LVDD with an AUC of 0.89 (95% CI 0.87–0.92), and was independently associated with hypertension, diabetes, and elevated C-reactive protein. While correlated with the Levine (r=0.76) and Horvath (r=0.41) epigenetic clocks, residual analyses indicated that Diastolic Age captures a distinct cardiac-specific dimension of biological aging. Over median follow-up of 4.2 years, it independently predicted MACE (HR 2.30, 95% CI 1.70–3.18), with accelerated diastolic aging across all age groups among those with events. Discrimination was comparable to ASE-defined LVDD (C-index 0.83 vs. 0.82). Conclusions: Diastolic Age provides a continuous, echocardiography-derived measure of cardiac biological aging that complements categorical diastolic grading and epigenetic aging clocks, and independently predicts cardiovascular outcomes.

  • Blood Pressure 15 to 90 Days After a Hypertensive Disorder of Pregnancy and Later Hypertension

    by Rachel Peragallo Urrutia, Matthew Shane Loop, Jasmine D. Johnson, Tracy Y. Wang, Thomas M. Price, Melissa A. Daubert

    BACKGROUND: Timely diagnosis of hypertension provides an opportunity for cardiovascular disease prevention after a hypertensive disorder of pregnancy. We assessed the association between blood pressure 15 to 90 days postpartum and incident hypertension after a hypertensive disorder of pregnancy. METHODS: This was a retrospective cohort study of women with no preexisting hypertension and a hypertensive disorder of pregnancy between January 2014 and December 2017 at 2 health systems in the southeastern United States. Cox proportional hazards models assessed the association of postpartum blood pressure and incident hypertension over a median follow-up period of 9.9 months. Covariates selected via directed acyclic graph construction included type of hypertensive disorder, race, ethnicity, maternal age, smoking, body mass index, and gestational diabetes. RESULTS: Out of 5657 women, only 2520 (45%) met the inclusion criteria; 39% (1584) of otherwise eligible individuals did not have a blood pressure check at 15 to 90 days postpartum. The hazards of incident hypertension during follow-up were significantly higher for those with higher systolic postpartum blood pressure (1.81 [95% CI, 1.46–2.24]). The estimated cumulative incidence of hypertension over the first 12 months of follow-up among participants with a blood pressure of 110/65 mm Hg was 4.5% (95% CI, 2.8%–6.1%), and with blood pressure 140/90, it was 12.0% (95% CI, 8.4%–17.2%). CONCLUSIONS: The risk of incident hypertension after a hypertensive disorder of pregnancy is high in the first year postpartum especially for those with elevated systolic blood pressure postpartum. Despite this, for many participants, blood pressure was not measured within 15 to 90 days postpartum.


  • Open Access

    Valvular Heart Disease Associations With Cardiac Biomarkers Using AI-Guided Echocardiography

    by Evangelia Alexopoulos, Joanna Walsh, Jesse Y. Hsu, Michael J. Blaha, Susan Cheng, Melissa A. Daubert, Gary Dunn, Peter Durda, Ervin Ray Fox, Yngvil Thomas, et al.


  • Open Access

    Acellular Tissue Engineered Vessels as Coronary Artery Bypass Grafts

    by Adam R. Williams, Kevin M. Nash, Robert D. Kirkton, Garyn S. Levitan, Melissa A. Daubert, Susan A. Whitney, Kaleb M. Naegeli, Abigail R. Benkert, Sharon L. McCartney, Heather L. Prichard, et al.


  • Impact of Coronary Artery Disease on Cardiovascular Outcomes Differs Between Men and Women With Severe Aortic Stenosis

    by Kayla Brown, Ke Xu, Rebecca T. Hahn, Philippe Pibarot, Jonathon A. Leipsic, Ying Ma, Marie-Annick Clavel, Sammy Elmariah, Neil J. Weissman, Federico M. Asch, et al.

    BACKGROUND: There is heterogeneity in coronary artery disease (CAD) severity among individuals with severe aortic stenosis (AS), but whether this differentially influences prognosis is unknown. METHODS: Patients with severe AS in the PARTNER 1, 2, and 3 trials and registries (Placement of Aortic Transcatheter Valves) were stratified by obstructive CAD (coronary stenosis ≥50%, prior myocardial infarction, or revascularization) or no obstructive CAD (all stenoses P =0.04), irrespective of AS treatment. However, there were significant differences by sex ( P interaction =0.0002). Men with no obstructive CAD had a 16% lower event rate compared with men with obstructive CAD (adjusted hazard ratio, 0.84 [CI, 0.73–0.96]; P =0.01). In contrast, women with no obstructive CAD did not have a significantly lower rate of death, stroke, or heart failure hospitalization compared with women with obstructive CAD (adjusted hazard ratio, 0.95 [CI, 0.85–1.07]; P =0.41). Women with no obstructive CAD had a more advanced heart failure phenotype and higher event rates compared with men with no obstructive CAD. CONCLUSIONS: Obstructive CAD was associated with a higher risk of long-term adverse events after treatment for severe AS, but there was a significant sex disparity in clinical outcomes among men and women with no obstructive CAD. Further study is needed to optimize the evaluation and management of women with severe AS.